Aratinga Bio - Reorg financing

Aratinga is a french/US company currently reorganizing.

Their technology is unique and disruptive.

The lentivector - encoding for the Chimeric Antigen Receptor (CAR)- is coated with a polymeric envelope. The anti-CD3 targeting moiety grafted at the surface of the polymer directs the synthetic vector towards the T-cells.'s in vivo technology does not require costly dedicated manufacturing sites to produce modified T-cells in contrast to approved ex vivo CAR T-cell therapies.

The genetic modification to express the CAR is directly generated in the patient.